Comparative Pharmacology
Head-to-head clinical analysis: HEDULIN versus HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEDULIN versus HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
HEDULIN vs HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HEDULIN (phenindione) is an anticoagulant that inhibits vitamin K-dependent synthesis of coagulation factors II, VII, IX, and X in the liver, thereby reducing thrombus formation.
Heparin binds to antithrombin III, accelerating its inhibition of thrombin (factor IIa) and factor Xa, thereby preventing fibrin clot formation.
Oral, 200-400 mg initially, then 100-200 mg every 6-12 hours; maximum daily dose 1200 mg.
Initial IV bolus of 80 units/kg, followed by continuous IV infusion at 18 units/kg/hour; subsequent dosing based on aPTT. For DVT/PE: initial bolus of 5,000 units or 80 units/kg, then 1,000-2,000 units/hour continuously.
None Documented
None Documented
Terminal elimination half-life is 18-24 hours in patients with normal renal function; may be prolonged to 30-40 hours in renal impairment, necessitating dose adjustment.
30–90 minutes (mean 1.5 h) for therapeutic doses; dose-dependent and saturable elimination: increases with dose (e.g., 100 U/kg: ~56 min; 400 U/kg: ~152 min). At lower doses, half-life may be shorter due to rapid clearance.
Renal excretion of unchanged drug accounts for approximately 70% of elimination; the remainder is metabolized hepatically and excreted in feces via bile.
Renal: minimal intact heparin; primarily hepatic degradation via desulfation and depolymerization into inactive metabolites (uroheparin) excreted renally. Biliary/fecal: negligible (<1%).
Category C
Category A/B
Anticoagulant
Anticoagulant